Qiagen (NYSE:QGEN) Given New $60.00 Price Target at JPMorgan Chase & Co.

Qiagen (NYSE:QGEN) had its price objective hoisted by JPMorgan Chase & Co. from $55.00 to $60.00 in a report released on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 17.52% from the stock’s current price.

A number of other brokerages also recently issued reports on QGEN. Barclays set a $58.00 price target on Qiagen and gave the company an “overweight” rating in a report on Friday. TD Cowen reiterated a “hold” rating on shares of Qiagen in a research note on Friday. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Deutsche Bank Aktiengesellschaft downgraded shares of Qiagen from a “buy” rating to a “hold” rating and upped their price objective for the stock from $52.00 to $54.00 in a research report on Thursday, January 22nd. Finally, Robert W. Baird set a $53.00 price target on Qiagen in a report on Friday. Four research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, Qiagen currently has a consensus rating of “Hold” and a consensus price target of $55.27.

Qiagen Stock Performance

Shares of NYSE:QGEN traded down $0.18 during midday trading on Friday, reaching $51.06. The company’s stock had a trading volume of 1,917,850 shares, compared to its average volume of 3,139,680. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45. The stock has a fifty day moving average of $49.63 and a 200 day moving average of $49.67. Qiagen has a twelve month low of $39.61 and a twelve month high of $57.81. The firm has a market capitalization of $10.78 billion, a PE ratio of 25.32, a P/E/G ratio of 2.48 and a beta of 0.67.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.61 by $0.01. The company had revenue of $540.42 million for the quarter, compared to analyst estimates of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.82%. The firm’s revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.61 earnings per share. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, equities analysts expect that Qiagen will post 2.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Qiagen

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Danske Bank A S acquired a new position in Qiagen during the third quarter worth $36,000. Smartleaf Asset Management LLC raised its holdings in shares of Qiagen by 1,383.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after acquiring an additional 830 shares during the period. MAI Capital Management boosted its position in shares of Qiagen by 998.9% during the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after acquiring an additional 889 shares during the last quarter. Global Retirement Partners LLC grew its holdings in shares of Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after purchasing an additional 851 shares during the period. Finally, Allworth Financial LP increased its position in Qiagen by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after purchasing an additional 796 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.